Patents Assigned to Flanders Interuniversity Institute for Biotechnology, VIB
  • METHOD FOR TREATING OCULAR CANCER
    Publication number: 20140121218
    Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.
    Type: Application
    Filed: December 5, 2013
    Publication date: May 1, 2014
    Applicants: St. Jude Children's Research Hospital, Leiden University Medical Center, Universiteit Gent, Flanders Interuniversity Institute for Biotechnology VIB
    Inventors: Michael A. Dyer, Jean-Christopher Marine, Aart Gerrit Jochemsen
  • Method for treating ocular cancer
    Patent number: 8614192
    Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.
    Type: Grant
    Filed: July 24, 2007
    Date of Patent: December 24, 2013
    Assignees: Leiden University Medical Center, Flanders Interuniversity Institute for Biotechnology, VIB, St. Jude Children's Research Hospital
    Inventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
  • Use of placental growth factor for treating ischemic muscle disease
    Patent number: 7727971
    Abstract: The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor or nucleic acids ensuring increased expression of a growth factor for treating, more particularly restoring the function of ischemic tissue, in particular muscles such as myocardium and skeletal muscles.
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: June 1, 2010
    Assignees: Life Sciences Research Partners VZW, Flanders Interuniversity Institute for Biotechnology (VIB)
    Inventors: Peter Carmeliet, Désiré Collen
  • Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke
    Patent number: 6930089
    Abstract: Vascular endothelial growth factor, placenta growth factor or combinations of both including heteodimers are useful in the treatment or prevention of stroke or ischemic diseases in mammals.
    Type: Grant
    Filed: February 5, 2001
    Date of Patent: August 16, 2005
    Assignees: D. Collen Research Foundation vzw, Flanders Interuniversity Institute for Biotechnology, VIB
    Inventor: Peter Carmeliet